“Our Last Biotech Takeover Pick Soared 461% and I Want You to Join Us on This One.”
●This biotech made history — winning the first and only FDA-approved T cell therapy for a solid-tumor cancer. It’s now expanding into lung cancer, endometrial cancer, and sarcoma.
●Multiple Wall Street firms rate this stock a “BUY” — with price targets as high as $16 per share... more than 4X the current price!
●Stock trades at under $4 a share, but we see a takeover happening north of $20 per share.